FLT3 and acute myeloid leukemia: Pratz et al. found that the addition of gilteritinib to a 7+3 regimen was associated with a cCR rate of 100% and an EFS of 9.7 months in a trial including older patients [69], and a phase III, randomized trial comparing 7+3 combined with midostaurin or gilteritinib in patients with newly diagnosed FLT3-mutated AML is now ongoing (NCT04027309).